Serotonin 5-HT1B Receptor Neurons represent a critical population of neurons expressing the 5-hydroxytryptamine 1B (5-HT1B) receptor, a Gi/o protein-coupled receptor that serves both as an autoreceptor on serotoninergic neurons and as a heteroreceptor on non-serotoninergic neurons throughout the brain. The 5-HT1B receptor is one of the most abundantly expressed serotonin receptors in the mammalian brain, with particularly high densities in the basal ganglia, hippocampus, cerebral cortex, and dorsal raphe nucleus. These receptor neurons play fundamental roles in modulating serotonin release, regulating mood and behavior, and influencing motor function. Growing evidence suggests that 5-HT1B receptor dysfunction contributes to the pathogenesis of several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, making them an important therapeutic target. [@p Sierra][@p abrams]
The 5-HT1B receptor is encoded by the HTR1B gene located on chromosome 6q13 in humans. Like other 5-HT1 family members, the 5-HT1B receptor contains seven transmembrane domains connected by extracellular and intracellular loops, with the N-terminus extracellular and the C-terminus intracellular. Upon agonist binding, the receptor activates Gi/o proteins that inhibit adenylate cyclase, reducing intracellular cAMP levels. This signaling cascade leads to opening of potassium channels, hyperpolarization of the neuronal membrane, and reduced neurotransmitter release. Additionally, 5-HT1B receptors can signal through β-arrestin-mediated pathways that affect gene transcription and cellular survival. The receptor exhibits constitutive activity in some brain regions, meaning that it can modulate neuronal function even in the absence of endogenous serotonin. [@p pg]
The 5-HT1B receptor has a distinctive pharmacological profile that distinguishes it from other serotonin receptor subtypes. Selective 5-HT1B agonists include sumatriptan (used clinically for migraine), zolmitriptan, and elatriptan, while selective antagonists such as GR-127935 and SB-216641 have been developed for research purposes. The receptor also displays affinity for certain atypical antipsychotics, notably aripiprazole, which acts as a partial agonist at 5-HT1B receptors. Endogenous ligands include serotonin itself and the trace amine β-phenylethylamine, which can modulate receptor activity. The development of biased agonists that selectively activate β-arrestin pathways while minimizing G protein signaling represents a promising direction for drug development. [@p b]
The highest densities of 5-HT1B receptors in the brain are found in the basal ganglia, particularly in the striatum (caudate nucleus and putamen), globus pallidus, and substantia nigra. Within the striatum, 5-HT1B receptors are primarily located on striatofugal neurons, especially those projecting to the globus pallidus externus (GPe) as part of the indirect pathway. Here, 5-HT1B receptors function as heteroreceptors that modulate GABA release from striatal neurons, thereby influencing motor output and action selection. The intense 5-HT1B receptor expression in the basal ganglia has important implications for movement disorders, as these receptors can modulate dopaminergic signaling and motor control. [@p abrams][@p masri]
The hippocampus contains moderate to high levels of 5-HT1B receptors, particularly in the CA3 region and dentate gyrus. In the hippocampus, 5-HT1B receptors are expressed on both excitatory glutamatergic neurons and inhibitory GABAergic interneurons. At presynaptic terminals, 5-HT1B receptors regulate glutamate release, influencing synaptic plasticity and spatial memory formation. Postsynaptic 5-HT1B receptors on hippocampal interneurons modulate inhibitory tone and network oscillations important for memory consolidation. Age-related declines in hippocampal 5-HT1B receptor function may contribute to cognitive decline in both normal aging and neurodegenerative diseases. [@p hj][@p mh]
5-HT1B receptors are widely distributed throughout the cerebral cortex, with higher densities in layer 4 and layer 6. Cortical 5-HT1B receptors are expressed on pyramidal neurons, interneurons, and presynaptic terminals where they modulate the release of multiple neurotransmitters including glutamate, GABA, and acetylcholine. These receptors contribute to cortical processing of sensory information, attention, and executive function. In the prefrontal cortex, 5-HT1B receptors play important roles in working memory and behavioral flexibility, functions that are compromised in several neurodegenerative conditions. [@p cc]
Within the dorsal raphe nucleus, 5-HT1B receptors function as autoreceptors on serotoninergic neurons, where they provide negative feedback that regulates serotonin release. Activation of these autoreceptors inhibits serotonin neuron firing and reduces synaptic serotonin availability in target regions. This autoregulatory function is critically important for maintaining serotonin system homeostasis and is a key target for antidepressant and anxiolytic drugs. Dysregulation of 5-HT1B autoreceptor function has been implicated in depression and may contribute to serotonin system abnormalities observed in neurodegenerative diseases. [@p bn]
In Alzheimer's disease (AD), 5-HT1B receptor expression and function are significantly altered in brain regions affected by amyloid and tau pathology. Post-mortem studies have demonstrated reduced 5-HT1B receptor binding in the hippocampus and frontal cortex of AD patients, correlating with cognitive impairment severity. These changes may reflect neuronal loss, downregulation of receptor expression, or disruption of serotoninergic innervation. Importantly, 5-HT1B receptor activation has been shown to protect against amyloid-beta-induced neurotoxicity in cell culture and animal models, suggesting that preserving or enhancing 5-HT1B receptor function could have therapeutic benefits in AD. The receptor's ability to modulate glutamate release and exert anti-excitotoxic effects appears to underlie this neuroprotection. [@p hj][@p cl]
Parkinson's disease (PD) involves prominent degeneration of dopaminergic neurons in the substantia nigra pars compacta, but serotoninergic dysfunction also contributes to both motor and non-motor symptoms. 5-HT1B receptors are abnormal in PD, with some studies reporting increased binding in the striatum and decreased binding in the cortex. The significance of these changes is complex, as 5-HT1B receptors can both inhibit and facilitate dopamine release depending on their location and the disease stage. Additionally, 5-HT1B receptors on non-serotoninergic neurons may contribute to non-motor symptoms such as depression, anxiety, and sleep disturbances that precede motor signs in PD. Preliminary studies suggest that 5-HT1B agonists may have symptomatic benefits in PD, possibly through modulation of basal ganglia circuitry. [@p masri][@p lin]
Huntington's disease (HD) is characterized by progressive loss of striatal and cortical neurons, accompanied by early and severe neuropsychiatric symptoms. 5-HT1B receptor expression is reduced in the striatum and cortex of HD patients and in mouse models of the disease. This reduction may contribute to the irritability, aggression, and depression that commonly affect HD patients. Notably, 5-HT1B receptor activation has been shown to protect against excitotoxic neuronal death in experimental models, suggesting potential neuroprotective applications. Additionally, 5-HT1B receptors modulate medium spiny neuron function and could influence the characteristic motor abnormalities in HD, including chorea and dystonia. [@p dn]
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. Serotoninergic system abnormalities, including changes in 5-HT1B receptor expression, have been documented in MSA. Studies have found altered 5-HT1B receptor binding in various brain regions of MSA patients, potentially contributing to the non-motor symptoms and autonomic dysfunction characteristic of this condition. The relationship between 5-HT1B receptor changes and other neurochemical abnormalities in MSA remains an active area of investigation. [@p mm]
One of the most important neuroprotective mechanisms of 5-HT1B receptors is their ability to modulate glutamatergic neurotransmission and protect against excitotoxicity. Excessive glutamate release and overactivation of NMDA receptors contribute to neuronal death in many neurodegenerative conditions. 5-HT1B receptor activation reduces glutamate release from presynaptic terminals, decreases NMDA receptor activity, and attenuates calcium influx into neurons. These effects are particularly relevant in conditions where excitotoxicity plays a major pathogenic role, including Alzheimer's disease, Parkinson's disease, and stroke. The anti-excitotoxic effects of 5-HT1B receptors may explain the protective effects observed in multiple neurodegenerative models. [@p cl]
Neuroinflammation is a hallmark of neurodegenerative diseases, and 5-HT1B receptors can modulate inflammatory responses in the brain. Activation of 5-HT1B receptors on microglia can reduce the production of pro-inflammatory cytokines and reactive oxygen species. This anti-inflammatory effect may contribute to neuroprotection in conditions where chronic neuroinflammation drives progressive neuronal loss. The serotonergic system thus provides a link between mood regulation and neuroimmune function, with implications for understanding the comorbidity of depression and neurodegenerative diseases.
5-HT1B receptor activation has been shown to influence the expression and release of neurotrophic factors, including brain-derived neurotrophic factor (BDNF). BDNF is critical for neuronal survival, synaptic plasticity, and cognitive function, and its levels are reduced in several neurodegenerative conditions. By enhancing BDNF expression and signaling, 5-HT1B receptors may promote neuronal resilience and support cognitive function. This mechanism may contribute to the cognitive benefits of 5-HT1B agonists observed in some experimental studies.
The 5-HT1B receptor was originally identified as the primary target of triptan drugs used to treat acute migraine attacks. Triptans cause vasoconstriction of cranial blood vessels and inhibit trigeminal nociceptor activation through 5-HT1B and 5-HT1D receptor activation. While the relevance of 5-HT1B receptors in migraine to neurodegenerative conditions is uncertain, this therapeutic success validates the receptor as a viable drug target and provides a template for developing neuroprotective agents based on 5-HT1B receptor modulation. [@p b]
Given the role of 5-HT1B receptors in regulating serotonin release and mood, these receptors represent potential targets for antidepressant and anxiolytic drug development. However, the complex autoreceptor and heteroreceptor functions of 5-HT1B make it challenging to achieve desired effects without unwanted side effects. Selective serotonin reuptake inhibitors (SSRIs) indirectly modulate 5-HT1B receptor activity through increased serotonin levels, but direct 5-HT1B agonists or positive allosteric modulators may provide more targeted approaches. The relationship between 5-HT1B receptor function and depression in neurodegenerative diseases deserves further investigation. [@p bn][@p v]
Preclinical studies suggest that 5-HT1B receptor modulation may improve cognitive function in certain contexts. Given the cognitive impairments that characterize Alzheimer's disease and other dementias, this represents a potentially important therapeutic application. However, the cognitive effects of 5-HT1B receptor manipulation are context-dependent and may vary with age, disease state, and brain region. Further research is needed to determine whether selective 5-HT1B modulators can provide cognitive benefits in human neurodegenerative conditions. [@p m]
Several important questions remain regarding the biology of 5-HT1B receptor neurons and their role in neurodegeneration. Key research priorities include: (1) determining the precise cellular and subcellular localization of 5-HT1B receptors in human brain using post-mortem tissue and imaging methods; (2) characterizing 5-HT1B receptor function in patient-derived cellular models of neurodegenerative diseases; (3) developing selective brain-penetrant 5-HT1B modulators with favorable pharmacological properties; (4) conducting clinical trials of 5-HT1B-targeted interventions in neurodegenerative conditions; and (5) investigating the interaction between 5-HT1B receptors and other therapeutic targets such as amyloid, tau, and alpha-synuclein. Advances in molecular imaging, stem cell models, and selective pharmacology will accelerate progress in each of these areas.